Shire fills in gaps

Shire Pharmaceutical Group plc already has tried once to reduce its reliance on sales of its Adderall for attention deficit hyperactivity disorder with the 1999 acquisition of Roberts Pharmaceutical Corp. But Adderall sales have grown 51 percent since August 1999, compared to a more modest 30 percent growth in sales

Read the full 503 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE